We are very excited to have Dr. David Fajgenbaum as our student-selected keynote speaker on this momentous occasion of our 50th commencement ceremony. His impressive and lofty goals and accomplishments will serve as a lasting inspiration to our students and anyone in attendance,” stated Dr. David Guzick, Chancellor of LSU Health Shreveport.
In September 2022, Fajgenbaum joined forces with longtime friend and fellow doctor Grant Mitchell, MD, and a group of experts at the University of North Carolina and beyond to leverage the power of machine learning to sift through the ocean of existing medical research to connect rare diseases to existing drugs. Their organization is called […]
Worldwide Clinical Trials (Worldwide), the industry’s leading global, full-service contract research organization (CRO), has partnered with Every Cure, a nonprofit organization that unlocks new, often undiscovered uses for existing approved drugs by leveraging data, artificial intelligence (AI), and efficient clinical trials.
David Fajgenbaum is an immunologist and co-founder of Every Cure, a nonprofit organization whose mission is to unlock the full potential of approved medicines to treat every disease possible. The organization, which he launched at the Clinton Global Initiative in 2022, employs AI to search through existing data to identify potential additional indications for approved […]
Fajgenbaum was having his last rites read to him, and his family braced for his death from Castleman disease, a rare inflammatory illness that impacts the lymph nodes and can severely damage other organs.
About a decade ago, David Fajgenbaum thought his life was over. He was a young, bright physician hoping to work in oncology in remembrance of his mother, who died of brain cancer a few years earlier. Fajgenbaum was having his last rites read to him, and his family braced for his death from Castleman disease, […]
David Fajgenbaum has become a “man on fire,” determined to repurpose as many generic drugs as possible for diseases without approved treatments. Fajgenbaum, whose efforts have been recognized by former President Bill Clinton, spoke with In Vivo about his own patient journey with a disease with no approved treatment and about the Every Cure Foundation, a non-profit […]
Two companies team up to combat rare diseases through drug repurposing, which was heavily informed by one doctor’s experience through unconventionally treating his Castleman disease and (ultimately) saving his own life. Two companies join forces to unlock the hidden potential in existing drugs to save lives suffering from rare diseases. In 2010, Dr. David Fajgenbaum, […]
David Fajgenbaum, MD, was a college football player at Georgetown University in 2004 when his mother passed away from cancer. The loss inspired the athlete to become a doctor himself: “I wanted to treat patients in memory of my mom,” he says. But three years into medical school, the then-25-year-old’s health took a turn for […]
As many as 7,000 rare diseases affect 300 million people globally. The vast majority are not well understood, and less than 5 percent have approved treatments. Yet, patients are meeting these challenges head-on. Dr. Fajgenbaum was diagnosed with Castleman disease, a rare disorder that involves an overgrowth of cells in your body’s lymph nodes. The most […]
Dr. David Fajgenbaum is not afraid to think outside the box and that is what saved his life. While in medical school, the former college athlete suddenly became critically ill. Doctors told him he was suffering from a rare disorder called Castleman disease; his immune system was attacking his vital organs, potentially leading to life-threatening […]
It was the night before April Fools’ Day, 2021, when Dr. David Fajgenbaum received the text: President Clinton read your book and would like to talk. Despite the outpouring of praise for his bestselling memoir, Chasing My Cure – an astounding chronicle of Fajgenbaum’s five near-death experiences from Castleman disease and his successful search to […]
The Philadelphia physician has the distinction of researching – and solving – his own rare disease. Learn more about this prolific advocate for rare disease patients. Maybe it’s the brush with death that David Fajgenbaum had at a young age that gave him an extra charge of energy, a powerful desire to get things done.
For biotechs, the JP Morgan Healthcare Conference is about dealmaking in many forms—securing financing, establishing development partnerships, courting mergers and acquisitions—by wooing would-be partners and investors with a value proposition. Everyone’s in schmooze-and-pitch mode, and everyone’s seeking to capitalize on the momentum the show generates in the news cycle.
Medable has announced a collaboration with non-profit Every Cure for conducting global, remote clinical trials for drug repurposing candidates. Every Cure was officially launched, in collaboration with the Clinton Global Initiative, in September to scale up a new ‘drug repurposing’ research approach for identifying rare disease treatments.
Medable Inc., the industry-leading technology platform for patient-centered clinical trials, today announced a partnership with non-profit Every Cure, which officially launched in September in partnership with the Clinton Global Initiative to scale up an innovative “drug repurposing” research approach to identify treatments for rare diseases.
This week, an exciting interview from our archive airs on Oct. 8, 2022. A healthy young medical student, David Fajgenbaum, had been a student athlete in college and maintained his extraordinary level of fitness through much of medical school. Because of his enthusiasm and athleticism, his friends called him The Beast. When he suddenly found […]
A new nonprofit backed by the Clinton Global Initiative aims to identify generic drugs that could help people with rare diseases. Every Cure is based on the concept that every drug on the market has multiple effects on the body, not just the one or two that first earned its approval.
Approximately 75% of human diseases don’t have a single FDA-approved treatment. That fact nearly cost Dr. David Fajgenbaum his life, and at #CGI2022, he announced a Commitment to Action that aims to change it:
Former President Bill Clinton is calling on governments, businesses, philanthropies and other prominent institutions to draw together and help a world that is “on fire” as he reconvenes the Clinton Global Initiative, the meeting of international leaders, for the first time since 2016.
A new nonprofit backed by the Clinton Global Initiative aims to identify generic drugs that could help people with rare diseases. Every Cure is based on the concept that every drug on the market has multiple effects on the body, not just the one or two that first earned its approval.
Every drug on the market has multiple effects on the body, not just the one or two that won it approval. A new nonprofit aims to exploit those other effects to help patients with rare diseases.
